Results 171 to 180 of about 43,704 (225)
Leukemic appendix with clinical presentation that mimics acute appendicitis. [PDF]
J HematopWeiss O, Wang Y.
europepmc +1 more source
Sequential nasal and mammary myeloid sarcoma with a 6-year latency: a case report and literature review. [PDF]
Front Med (Lausanne)Yu J, Hou C, Xu F.
europepmc +1 more source
Acute promyelocytic leukaemia presenting with gingival hypertrophy: an atypical oral presentation. [PDF]
Oxf Med Case ReportsAntiri EK, Ekem IAE.
europepmc +1 more source
Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. [PDF]
Am J Blood ResDhariwal N, Srinivasan S.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Pediatric Oncology Nursing, 1990
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing to investigate high-dose therapy with cytarabine.
D L, Betcher, N, Burnham
openaire +3 more sources
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing to investigate high-dose therapy with cytarabine.
D L, Betcher, N, Burnham
openaire +3 more sources
Cytarabine ears – A side effect of cytarabine therapy
Journal of Oncology Pharmacy Practice, 2019Cytarabine, a pyramidine analog, is used for treating various hematological malignancies such as acute leukemias and lymphomas. Side effects of cytarabine are dose dependent and include bone marrow suppression, fever, cerebellar toxicity, cardiomyopathy, hepato-renal insufficiency, necrotizing enterocolitis, pancreatitis, acute respiratory distress ...
Divya Doval +4 more
openaire +2 more sources
Clinical Pharmacology & Therapeutics, 1970
Warning. Only physicians experienced in cancer chemotherapy should use Cytosar. For induction therapy patients should be hospitalized in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.
openaire +2 more sources
Warning. Only physicians experienced in cancer chemotherapy should use Cytosar. For induction therapy patients should be hospitalized in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity.
openaire +2 more sources
Drug Safety, 1990
The principal toxicity of standard induction regimens for acute non-lymphocytic leukemia (ANLL) [including cytarabine (ARA-C) 100 mg/m2 for 7 days plus an anthracycline] is myelotoxicity, leading to death in at least 25% of cases during induction in non-selected patients.
openaire +2 more sources
The principal toxicity of standard induction regimens for acute non-lymphocytic leukemia (ANLL) [including cytarabine (ARA-C) 100 mg/m2 for 7 days plus an anthracycline] is myelotoxicity, leading to death in at least 25% of cases during induction in non-selected patients.
openaire +2 more sources